Mylan (NSDQ:MYL) today announced the launch of its Wixela Inhub product, a generic for GlaxoSmithKline‘s (NYSE:GSK) Advair Diskus device, for people with asthma or chronic obstructive pulmonary disease.
The company touted that its device’s list price is 70% less than Advair Diskus and 67% less than GSK’s generic.
Get the full story at our sister site, Drug Delivery Business News.
The post Touting pricetag, Mylan launches Advair generic appeared first on MassDevice.